Biotech

Applied DNA journeys deeper into India, and pharma

By GREGORY ZELLER // A new professional collaboration will deepen a Long Island biotech’s ties with global pharmaceutical and nutraceutical manufacturers. Stony Brook-based Applied DNA Sciences has signed a memorandum of understanding with India-based global pharmaceutical conglomerate ACG Worldwide, which is tapping into the Long Island firm’s molecular-based authentication services. The MoU – which is “expected to be followed by a definitive agreement,” according to Applied DNA – will apply the biotech’s SigNature molecular tagging…


NIH backs SBU-based biotech’s tuberculosis effort

By GREGORY ZELLER // A Setauket-based pharmaceuticals startup specializing in biomarker analysis has landed a chunky National Institutes of Health research award. Chronus Pharmaceuticals, founded and managed by researchers representing Stony Brook University and an assortment of other prestigious research institutions, announced this week that it has received a $299,172 Phase I Small Business Technology Transfer award from the NIH’s National Institute of Allergy and Infectious Diseases. The award, received in partnership with SBU’s Department…


Smoking-hot biotech sparks key cannabis contract

By GREGORY ZELLER // It’s another new high for Applied DNA Sciences. Just days after introducing a new satellite laboratory in India to service its growing Asian-Pacific customer base, the Stony Brook-based biotech lit up again Thursday, announcing a new contract to develop molecular tracking systems for a worldwide network of legal cannabis supplies. The two-year, $1 million development and marketing agreement with Canadian supplier TheraCann International Benchmark Corp. – which provides turn-key pharmaceutical solutions…


For Applied DNA, a lucrative new passage to India

By GREGORY ZELLER // Growing interest from Asian-Pacific textile manufacturers has prompted a Long Island biotech to establish a new testing laboratory in India. Stony Brook-based Applied DNA Sciences on Tuesday announced the opening of its new Central DNA Testing Laboratory in Ahmedabad, a city of 5.6 million residents in the Western India state of Gujarat, a manufacturing and distribution hub advancing cotton and other textiles, as well as fertilizers, petrochemicals and pharmaceuticals. From there,…


Applied DNA catches Irish robber blue/green-handed

By GREGORY ZELLER // Already the bane of Swedish car thieves, Applied DNA Sciences has now notched its first armed-robbery criminal conviction in Ireland. The latest international adventure for the Stony Brook-based anti-theft and product-authentication specialist and its ever-evolving roster of vertical markets takes us to the Emerald Isle, where evidence gathered through the biotech’s SigNature DNA platform has helped convict a thug involved in a violent theft. According to Applied DNA, the case involves…


Missiles, cars, leather … finally, biotech pushes pills

By GREGORY ZELLER // A biotech with a penchant for leather, foreign automobiles, high-tech weaponry and next-gen digital imaging is finally getting around to pharmaceuticals. Actually, that’s not true – Stony Brook-based Applied DNA Sciences has already this year announced multiple pharma-nutra-focused forays, including the production of DNA chains for in-vitro diagnostic and DNA-based therapeutic research purposes. But in announcing a technology license memorandum of understanding with Pennsylvania-based “hard dose” specialist Colorcon Inc., Applied DNA…


CSHL conference lands a bull’s eye on Lyme detection

By GREGORY ZELLER // A gaggle of academic, public health and commercial-healthcare specialists gathered under Cold Spring Harbor Laboratory’s mighty banner have published findings that could rewrite the book on Lyme disease detection. When the laboratory-diagnostics experts convened for a 2016 Banbury Center meeting – such gatherings, held at CSHL’s on-campus think tank, are generally regarded among the best international scientific workshops – they focused on Lyme, and specifically, earlier detection of a disease that…


Applied DNA is talking Turkey (and West Africa, too)

By GREGORY ZELLER // Applied DNA Sciences is in one of those modes again: another week, another big leap into a potentially lucrative geographic or vertical market. This week, it’s geographic, with a new federal mandate in the Republic of Turkey aiding the Stony Brook biotech’s efforts to develop new business there. Applied DNA on Tuesday announced plans to introduce DNA-tagged fertilizer to Turkey and countries in West Africa and Asia, amidst strong interest in…


As biopharma blossoms, ace DNA producer locks in

By GREGORY ZELLER // Applied DNA Sciences has long proclaimed textiles – your cotton shirt, your leather shoes and the industries that produce them – as its primary vertical market, the ideal sector in which to apply its patented DNA-based security and authentication protocols. But a wholly different use for its coveted DNA supplies may soon eclipse textile-tracking as the Stony Brook biotech’s primary moneymaker. That’s the word from President and CEO James Hayward, who…


Defense Logistics Agency re-ups on DNA markers

A federal contract extension will keep Applied DNA Sciences knee-deep in microcircuits for another year at least. The Stony Brook biotech said Monday that the Defense Logistics Agency has awarded a one-year extension of a 2014 deal through which the supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist applies its SigNature DNA biomarkers to microcircuits at the DLA’s Ohio-based Land and Maritime facility. Financial terms of the contract extension were not disclosed. But continuing to mark and…


Applied DNA earns new SigNature patent, more T’d up

By GREGORY ZELLER // Applied DNA Sciences has added two new U.S. patents to its impressive collection – at least, a new patent-and-a-half. The Stony Brook-based supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist announced this week the arrival of U.S. Patent No. 9,790,538, covering “Alkaline Activation for Immobilization of DNA Taggants” – essentially, protecting the core technology powering Applied DNA’s SigNature T molecular tags. The biotech also announced a Notice of Allowance on U.S. Patent Application…


With license and library deals, biotech spreads its DNA

By GREGORY ZELLER // It’s been a banner month for Applied DNA Sciences, with two new deals both reaffirming the biotech’s scientific value and significantly extending its commercial reach. On Friday, the provider of DNA-focused supply chain, anti-counterfeiting and anti-theft technologies announced that its SigNature molecular tag technology had been added to global materials-innovator Material ConneXion’s prestigious library – exposing Applied DNA’s wares to scientists, manufacturers and makers around the world, a potentially enormous commercial…


Codagenix scores again: $3M to hunt down deadly RSV

By GREGORY ZELLER // A fresh $3 million in public and private investments has set Codagenix Inc. on the trail of another nefarious disease. Already developing vaccines for Zika virus, the mutating menace Influenza A and a host of other viral villains, Codagenix will now focus its vaccine-creation might on Respiratory Syncytial Virus through a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health and another $1.5 million in…


In REDC love fest, CSHL kicks off $75M makeover

By GREGORY ZELLER // There was another major advance for biochemistry Thursday at Cold Spring Harbor Laboratory, but this one didn’t involve gas chromatographs or infrared spectrometers or a single test tube. Just a shovel. With Gov. Andrew Cuomo and a host of regional and state representatives on hand, the world-class scientific research facility officially broke ground on the renovation of its Demerec Laboratory, one of four CSHL laboratories being remade with a big assist…


NIH sees a need for speed in Traverse Biosciences

By GREGORY ZELLER // The National Institutes of Health has welcomed a rising Stony Brook biotech into its competitive Commercialization Accelerator Program. Traverse Biosciences, which is attempting to commercialize novel drug candidates for the treatment of inflammatory diseases affecting animals and humans, has landed one of 80 annual slots in the CAP, a nine-month program hosted by the NIH and the Larta Institute, a California-based networking group promoting international innovation. The NIH CAP – which…